724MO Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC)

Autor:	Igor Bondarenko, I. Lugowska, T. Meniawy, Anna Kryzhanivska, Marek Ancukiewicz, Bradley J. Monk, M. Neffa, I.V. Bulat, W.I. Ortuzar Feliu, T. Melkadze, David M. O'Malley
Rok vydání:	2021
Předmět:	Oncology Cervical cancer medicine.medical_specialty business.industry Anti pd 1 Phases of clinical research Hematology Anti ctla 4 medicine.disease Internal medicine medicine In patient business
Zdroj:	Annals of Oncology. 32:S727
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2021.08.1167
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::aca0432b8efbe107bb2f494261d02070 https://doi.org/10.1016/j.annonc.2021.08.1167 Zobrazit plný text záznamu